Arcoxia is a selective COX-2 inhibitor which is manufactured by pharmaceutical giant Merck. Containing the active ingredient etoricoxib, Arcoxia is the original brand name form of the ingredient which is now approved for sale in nearly 100 countries worldwide. Arcoxia selectively inhibits COX-2 which reduces the incidence of prostaglandins produced from arachidonic acid. Compared to traditional NSAID's which exhibit stronger COX-1 activity, Arcoxia is associated with less gastrointestinal side effects.
Arcoxia, being the original form of the drug can be used with great confidence by patients for whom this offers a potent painkilling benefit and with a reduced risk of side effects compared to NSAID drugs.
Arcoxia is licensed to treat a wide range of conditions including various forms of arthritis, ankylosing spondylitis, chronic lower back pain, acute pain and gout. In addition, Arcoxia is sometimes used to help reduce post-operative pain.
Arcoxia's dosing regime will vary based on the individual's condition and the assessment of the physician in charge of treatment. Always refer to product literature.